SOPHiA GENETICS S.A.
HealthcareNASDAQ:SOPH · NASDAQ Global Select
-$0.32 today
Vol 0.09M · Avg 0.10M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$81.2M of revenue converted into -$80.9M of net income for the selected period. Gross margin is 67.2% and net margin is -100.7%, showing how much revenue survives after costs and taxes. EPS is $-1.18, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $77.3M +18.6% | $65.2M +4.5% | $62.4M +31.1% | $47.6M +17.6% | $40.5M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $29.5M +38.7% | $21.2M +9.1% | $19.5M +19.3% | $16.3M +7.1% | $15.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $47.8M +8.8% | $43.9M +2.4% | $42.9M +37.3% | $31.3M +23.9% | $25.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 61.9% -5.5pp | 67.4% -1.4pp | 68.8% +3.1pp | 65.7% +3.4pp | 62.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $33.6M -2.3% | $34.4M -7.0% | $37.0M +4.5% | $35.4M +33.1% | $26.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $85.2M +11.6% | $76.3M -6.6% | $81.7M -2.8% | $84.1M +19.7% | $70.2M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $118.7M +7.5% | $110.5M -6.1% | $117.7M -1.1% | $119.1M +23.1% | $96.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $9.5M +10.9% | $8.6M +3.1% | $8.3M +49.6% | $5.6M +54.4% | $3.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$64.4M -26.9% | -$50.8M +27.0% | -$69.6M +14.5% | -$81.4M -17.5% | -$69.2M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -83.3% -5.5pp | -77.9% +33.7pp | -111.5% +59.6pp | -171.1% +0.1pp | -171.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$70.9M -6.5% | -$66.6M +11.0% | -$74.8M +14.8% | -$87.8M -22.8% | -$71.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -91.8% +10.4pp | -102.1% +17.8pp | -120.0% +64.7pp | -184.7% -7.9pp | -176.7% | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.9M -44.3% | $3.4M -26.1% | $4.5M +243.4% | $1.3M +6520.0% | $20.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $4.6M +138.1% | $1.9M +225.3% | $588.0K -8.0% | $639.0K -2.9% | $658.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$7.6M -242.7% | $5.3M +244.4% | -$3.7M -1641.6% | $238.0K +111.8% | -$2.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$78.5M -28.1% | -$61.3M +21.9% | -$78.5M +10.4% | -$87.6M -19.2% | -$73.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -101.6% -7.6pp | -94.0% +31.8pp | -125.9% +58.3pp | -184.2% -2.4pp | -181.7% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $512.0K -58.1% | $1.2M +151.6% | $486.0K +457.4% | -$136.0K -181.0% | $168.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$79.0M -26.4% | -$62.5M +20.9% | -$79.0M +9.7% | -$87.4M -18.7% | -$73.7M | $4.9B | $4.8B | $4.7B |
| Net Margin | -102.2% -6.3pp | -95.9% +30.7pp | -126.6% +57.2pp | -183.9% -1.7pp | -182.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -23.2% | -$1 +22.1% | -$1 +10.3% | -$1 -2.3% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -23.2% | -$1 +22.1% | -$1 +10.3% | -$1 -2.3% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $67.5M +2.7% | $65.8M +1.6% | $64.8M +1.0% | $64.1M +15.9% | $55.3M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $67.5M +2.7% | $65.8M +1.6% | $64.8M +1.0% | $64.1M +15.9% | $55.3M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.88B
Alto Neuroscience, Inc.
NYSE:ANRO
$753.47M
National Research Corporation
NASDAQ:NRC
$423.46M
Simulations Plus, Inc.
NASDAQ:SLP
$329.75M
Cellectis S.A.
NASDAQ:CLLS
$310.29M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$296.96M
AC Immune S.A.
NASDAQ:ACIU
$235.10M
OptimizeRx Corporation
NASDAQ:OPRX
$98.14M
Definitive Healthcare Corp.
NASDAQ:DH
$88.59M
Nakamoto Inc.
NASDAQ:NAKA
$75.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does SOPH generate?
SOPHiA GENETICS S.A. (SOPH) reported $77.27M of revenue in fiscal 2025.
Is SOPH profitable?
SOPHiA GENETICS S.A. (SOPH) reported -$78,999,000.00 of net income, with a net margin of -102.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.